Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim F Greten

Showing results (191-200 of 223) with videos related to

Pageof 23
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
Journal of Hepatology|April 4, 2022
Metformin treatment rescues CD8<sup>+</sup> T-cell response to immune checkpoint inhibitor therapy in mice with NAFLDSimon Wabitsch, Justin D McCallen, Olena Kamenyeva, et al.
Gut|July 10, 2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2020
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2021
Correction: Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Science (New York, N.Y.)|May 26, 2018
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cellsChi Ma, Miaojun Han, Bernd Heinrich, et al.
Cancer Cell|September 2, 2022
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLDChi Ma, Qiong Fu, Laurence P Diggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2015
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancerDung T Le, Andrea Wang-Gillam, Vincent Picozzi, et al.
Pageof 23

Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Acta Oncologica (Stockholm, Sweden)|May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
Journal of Hepatology|April 4, 2022
Metformin treatment rescues CD8<sup>+</sup> T-cell response to immune checkpoint inhibitor therapy in mice with NAFLDSimon Wabitsch, Justin D McCallen, Olena Kamenyeva, et al.
Gut|July 10, 2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2020
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2021
Correction: Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Science (New York, N.Y.)|May 26, 2018
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cellsChi Ma, Miaojun Han, Bernd Heinrich, et al.
Cancer Cell|September 2, 2022
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLDChi Ma, Qiong Fu, Laurence P Diggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2015
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancerDung T Le, Andrea Wang-Gillam, Vincent Picozzi, et al.
Pageof 23